RBF Capital’s Cue Biopharma CUE Stock Holding History

RBF Capital’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-667	Closed	-$45K	–	543
2022 Q3	$45K	Sell	667 -666	-50%	-$57.3K	﹤0.01%	515
2022 Q2	$100K	Buy	+1,333	New	+$156K	0.01%	497

Other funds holding CUE

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

RSWM

Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RBF Capital's CUE Position: Q4 2022 in Review

RBF Capital sold out of Cue Biopharma (CUE) in Q4 2022, closing a stake of 667 shares — an estimated $45K sold.

RBF Capital first reported a position in CUE in Q2 2022 and held it in 2 quarters. The position peaked at $100K in Q2 2022. 61 funds tracked by Wall St. Rank hold CUE as of Q4 2022.

RBF Capital reported no remaining Cue Biopharma position as of Q4 2022 after selling out during the quarter.
RBF Capital sold 667 Cue Biopharma shares in Q4 2022, an estimated $45K.
RBF Capital first reported a position in Cue Biopharma in Q2 2022 and held it in 2 quarters.
RBF Capital's Cue Biopharma position peaked at $100K in Q2 2022.
61 funds tracked by Wall St. Rank held Cue Biopharma as of Q4 2022.

Based on RBF Capital's 13F filing for Q4 2022, filed 14 Feb 2023.